AI
HAE icon

Axiom Investors’s Haemonetics HAE Stock Holding History

Axiom Investors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-12,900
Closed -$1.16M – 117
2020
Q2 		$1.16M Sell
12,900
-18,170
-58% -$1.84M 0.02% 107
2020
Q1 		$3.1M Sell
31,070
-14,980
-33% -$1.62M 0.08% 81
2019
Q4 		$5.29M Sell
46,050
-3,234
-7% -$391K 0.12% 73
2019
Q3 		$6.22M Sell
49,284
-1,011
-2% -$128K 0.17% 60
2019
Q2 		$6.05M Buy
50,295
+27,543
+121% +$2.71M 0.17% 65
2019
Q1 		$1.99M Sell
22,752
-21,317
-48% -$1.94M 0.06% 97
2018
Q4 		$4.41M Buy
+44,069
New +$4.63M 0.15% 73

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axiom Investors's HAE Position: Q3 2020 in Review

Axiom Investors sold out of Haemonetics (HAE) in Q3 2020, closing a stake of 12,900 shares — an estimated $1.16M sold.

Axiom Investors first reported a position in HAE in Q4 2018 and held it in 7 quarters. The position peaked at $6.22M in Q3 2019. 268 funds tracked by Wall St. Rank hold HAE as of Q3 2020.

  • Axiom Investors reported no remaining Haemonetics position as of Q3 2020 after selling out during the quarter.
  • Axiom Investors sold 12,900 Haemonetics shares in Q3 2020, an estimated $1.16M.
  • Axiom Investors first reported a position in Haemonetics in Q4 2018 and held it in 7 quarters.
  • Axiom Investors's Haemonetics position peaked at $6.22M in Q3 2019.
  • 268 funds tracked by Wall St. Rank held Haemonetics as of Q3 2020.

Based on Axiom Investors's 13F filing for Q3 2020, filed 12 Nov 2020.